Key facts
- It has raised $30.1M; the latest was Early Stage VC ($20.0M) in Sep 2025.
- Notable investors include Pareto Holdings, Raptor Group, Innovation Endeavors, Ground Up Ventures, Character (VC) — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Weave
- ·The full record, as it builds
Funding rounds
No funding rounds for Weave are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Weave
Developer of an AI-enabled platform designed for generating regulatory submissions, including investigational drug applications. The company's platform automates clinical note abstraction pipelines, linking multimodal datasets and accelerating the discovery of all data modalities with the help of regulatory, research, and development (R&D), and clinical teams to collaborate, organize, edit, and summarize source materials into a submission-ready IND in a day, enabling researchers to make informed decisions while developing drugs.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2022
- Employees
- 30
- Website
- weave.bio/
- Ownership
- Privately Held (backing)
Weave doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Weave shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Weave in its N-PORT filings yet. We sweep new filings monthly.